Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
Anavex Life Sciences (Nasdaq: AVXL) has appointed Professor Dr. Audrey Gabelle, MD, PhD to its Scientific Advisory Board. Dr. Gabelle, a specialist in predictive, personalized medicine and digital health in Alzheimer's disease, brings extensive expertise as a Professor of Neurology at Montpellier University.
Dr. Gabelle's credentials include managing 400+ memory centers within the French network, authoring 200+ peer-reviewed scientific papers, and 10+ years of experience in clinical Phase I-IV trials. She has expertise in diagnosis and biomarkers through the NeuroCognition biobank, which contains over 35,000 samples. Her recent focus includes real-world evidence, digital health strategies, and AI, with training from Columbia and Harvard Universities.
The appointment aims to support the development of blarcamesine (ANAVEX®2-73), an oral treatment for Alzheimer's disease that has shown clinically meaningful improvement and good safety profile.
Anavex Life Sciences (Nasdaq: AVXL) ha nominato la Prof.ssa Dr.ssa Audrey Gabelle, MD, PhD, nel suo Comitato Scientifico Consultivo. La Dr.ssa Gabelle, specialista in medicina predittiva, personalizzata e salute digitale nell'Alzheimer, porta una vasta esperienza come Professore di Neurologia presso l'Università di Montpellier.
Le credenziali della Dr.ssa Gabelle includono la gestione di oltre 400 centri per la memoria nella rete francese, la pubblicazione di più di 200 articoli scientifici peer-reviewed e oltre 10 anni di esperienza in studi clinici di Fase I-IV. È esperta in diagnosi e biomarcatori grazie alla biobanca NeuroCognition, che contiene più di 35.000 campioni. Il suo recente interesse riguarda l'evidenza nel mondo reale, le strategie di salute digitale e l'intelligenza artificiale, con formazione presso le Università di Columbia e Harvard.
La nomina ha l'obiettivo di supportare lo sviluppo di blarcamesina (ANAVEX®2-73), un trattamento orale per l'Alzheimer che ha dimostrato un miglioramento clinicamente significativo e un buon profilo di sicurezza.
Anavex Life Sciences (Nasdaq: AVXL) ha nombrado a la Profesora Dra. Audrey Gabelle, MD, PhD, en su Consejo Asesor Científico. La Dra. Gabelle, especialista en medicina predictiva, personalizada y salud digital en la enfermedad de Alzheimer, aporta una amplia experiencia como Profesora de Neurología en la Universidad de Montpellier.
Las credenciales de la Dra. Gabelle incluyen la gestión de más de 400 centros de memoria dentro de la red francesa, la autoría de más de 200 artículos científicos revisados por pares y más de 10 años de experiencia en ensayos clínicos de Fase I-IV. Tiene experiencia en diagnóstico y biomarcadores a través del biobanco NeuroCognition, que contiene más de 35,000 muestras. Su enfoque reciente incluye evidencia del mundo real, estrategias de salud digital e inteligencia artificial, con formación en las universidades de Columbia y Harvard.
El nombramiento busca apoyar el desarrollo de blarcamesina (ANAVEX®2-73), un tratamiento oral para el Alzheimer que ha demostrado una mejora clínicamente significativa y un buen perfil de seguridad.
Anavex Life Sciences (나스닥: AVXL)는 Audrey Gabelle 박사(MD, PhD)를 과학 자문 위원회에 임명했습니다. Gabelle 박사는 알츠하이머병 예측 맞춤 의학 및 디지털 헬스 분야의 전문가로 몽펠리에 대학교 신경학 교수로서 풍부한 경험을 갖추고 있습니다.
Gabelle 박사의 경력에는 프랑스 내 400개 이상의 기억 센터 관리, 200편 이상의 동료 심사 과학 논문 저술, 임상 1~4상 시험에서 10년 이상의 경험이 포함됩니다. 그녀는 35,000개 이상의 샘플을 보유한 NeuroCognition 바이오뱅크를 통한 진단 및 바이오마커 분야의 전문가입니다. 최근에는 실제 데이터 기반 증거, 디지털 헬스 전략, 인공지능에 집중하며 콜롬비아 및 하버드 대학에서 교육을 받았습니다.
이번 임명은 임상적으로 유의미한 개선과 우수한 안전성을 보인 알츠하이머 구강 치료제 blarcamesine (ANAVEX®2-73) 개발을 지원하기 위한 것입니다.
Anavex Life Sciences (Nasdaq : AVXL) a nommé la Professeure Dr Audrey Gabelle, MD, PhD, au sein de son Conseil consultatif scientifique. Dr Gabelle, spécialiste de la médecine prédictive, personnalisée et de la santé numérique dans la maladie d'Alzheimer, apporte une expertise approfondie en tant que Professeure de neurologie à l'Université de Montpellier.
Les qualifications de Dr Gabelle comprennent la gestion de plus de 400 centres de la mémoire dans le réseau français, la rédaction de plus de 200 articles scientifiques évalués par des pairs, et plus de 10 ans d'expérience dans les essais cliniques de phases I à IV. Elle est experte en diagnostic et biomarqueurs grâce à la biobanque NeuroCognition, qui contient plus de 35 000 échantillons. Ses travaux récents portent sur les preuves issues du monde réel, les stratégies de santé numérique et l'IA, avec une formation aux universités de Columbia et Harvard.
Cette nomination vise à soutenir le développement de la blarcamesine (ANAVEX®2-73), un traitement oral de la maladie d'Alzheimer ayant démontré une amélioration cliniquement significative et un bon profil de sécurité.
Anavex Life Sciences (Nasdaq: AVXL) hat Professor Dr. Audrey Gabelle, MD, PhD, in seinen Wissenschaftlichen Beirat berufen. Dr. Gabelle, Spezialistin für prädiktive, personalisierte Medizin und digitale Gesundheit bei Alzheimer, bringt umfangreiche Erfahrung als Neurologie-Professorin an der Universität Montpellier mit.
Zu Dr. Gabelles Qualifikationen gehören die Leitung von über 400 Gedächtniszentren im französischen Netzwerk, die Veröffentlichung von über 200 begutachteten wissenschaftlichen Artikeln sowie mehr als 10 Jahre Erfahrung in klinischen Studien der Phasen I-IV. Sie ist Expertin für Diagnostik und Biomarker durch die NeuroCognition-Biobank, die mehr als 35.000 Proben enthält. Ihr aktueller Fokus liegt auf Real-World-Evidence, digitalen Gesundheitsstrategien und KI, mit Ausbildungen an den Universitäten Columbia und Harvard.
Die Ernennung soll die Entwicklung von blarcamesine (ANAVEX®2-73) unterstützen, einer oralen Behandlung für Alzheimer, die klinisch bedeutsame Verbesserungen und ein gutes Sicherheitsprofil gezeigt hat.
- Strategic addition of renowned Alzheimer's disease expert to Scientific Advisory Board
- Appointment brings expertise in digital health and AI to support drug development
- Addition of leader with extensive clinical trial experience (10+ years in Phase I-IV)
- Access to significant research network and biobank with 35,000+ samples
- None.
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board.
Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University. Dr. Gabelle is also researcher at the Montpellier Institute of Neurosciences and member of the European Alzheimer’s Disease Consortium.
Professor Dr. Gabelle is an accomplished leader with 10+ years of experience driving innovation in addition to 10+ years of experience in clinical Phase I-IV trials. She managed 400+ memory centers within the French network. She has a strong publication record with 200+ peer reviewed scientific papers, and is experienced in public-private partnerships, and collaborating with pharmaceutical companies. She was also founding member of research projects both at the European and global level and collaborates with international teams.
Professor Dr. Gabelle has expertise in diagnosis, predictive and prognosis biomarkers with the creation of the NeuroCognition biobank since 2007, including more than 35,000 samples with CSF, plasma proteomics profile, and clinical data including follow-up. She is involved in cohorts from population-based Three-City Study (3C Study) to clinical cohorts, including the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) study, a system supporting Memory and Moments of people with Early and Middle stage of dementia (MEMENTO), the Multidomain Alzheimer Preventive Trial (MAPT study), and the European Prevention of Alzheimer's Dementia (EPAD) longitudinal cohort study, to determine risk stratification and preventive strategies at early stage of neurodegenerative processes.
Recently, she focused on real-world evidence (RWE), digital health strategies and Artificial Intelligence (AI), honed through training at Columbia University, Harvard University Executive Leadership and prior leadership of digital initiatives at Biogen, including the Intuition Study with Apple, published in Nature Medicine.
“I’m thrilled to join Anavex’s Scientific Advisory Board given the convincing profile of blarcamesine as a potentially relevant treatment for patients with Alzheimer’s disease,” said Professor Dr. Gabelle. “There is a tremendous unmet medical need around the globe caused by Alzheimer’s disease. I look forward to collaborating on cutting-edge science and helping guide the development of new therapies that can make a meaningful impact on neurodegenerative disorders. A small molecule administered orally once daily, with demonstrated clinically meaningful improvement and good safety profile could be a game changer for patients, health care burden and equity of access to care. I am committed to leveraging my experience, and to supporting the Anavex Life Sciences Company’s ambition of improving lives through novel precision medicine such as blarcamesine.”
“We are delighted to welcome Professor Dr. Gabelle to Anavex’s Scientific Advisory Board,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Professor Dr. Gabelle brings broad expertise in Alzheimer’s disease combined with Digital Health to Anavex. I look forward to her active contributions in the process of advancing blarcamesine (ANAVEX®2-73) to patients diagnosed with Alzheimer’s disease.”
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
What is the significance of Dr. Gabelle joining AVXL's Scientific Advisory Board?
What are Dr. Gabelle's key achievements and experience relevant to AVXL?
How could blarcamesine (ANAVEX®2-73) benefit Alzheimer's patients?
What is Dr. Gabelle's role in advancing AVXL's Alzheimer's treatment research?
